HealthBeacon SHA

Environmental & Social Information • Feb 21, 2022

National Storage Mechanism | Additional information

RNS Number : 2086C

HealthBeacon PLC

21 February 2022

Peer Review validates the impact of HealthBeacon's Injection Care Management System

Research shows 26% improvement in medication adherence with HealthBeacon technology

HealthBeacon plc ("HealthBeacon" or the "Company"), the leading Irish digital therapeutics company, is pleased to announce that new peer reviewed evidence demonstrates a 26% improvement in medication adherence by patients using the Company's Injection Care Management System (ICMS).

The results of HealthBeacon's latest study, published in the prestigious International Journal of Clinical Pharmacy, proves the significant impact the Company's ICMS can have on medication adherence for patients across a range chronic, autoimmune conditions.

HealthBeacon's ICMS tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence driven data analytics.

This Medication Adherence study represents the Company's 6th peer reviewed study of Injection Care Management and Adherence. HealthBeacon's previous publications include studies on Medication Persistence, Medication Adherence Prediction, Digital Health Technology Adoption, Adherence to Injectable Growth Hormone and Virtual Injection Training.

On April 7th HealthBeacon's data and medical team will be hosting a webinar and presenting its full portfolio of peer reviewed publications for the clinical community and healthcare organisations across Europe, UK and the USA that are looking to improve patient support and engagement for patients on self-administered injectable medications. To register for the event, go to www.healthbeacon.com/webinars

Jim Joyce, CEO, and co-founder of HealthBeacon, commented: "It is well documented that approximately one in every two of patients fail to adhere to a specified regimen when long-term medication is prescribed. Medication non-adherence is a serious problem which affects both patients and healthcare systems, resulting in disease, death, and costs. HealthBeacon's technology offers a solution to some of these issues through the world's first FDA-cleared Smart Sharps Bin that is clinically proven to materially enhance medication adherence. HealthBeacon's technology and services supports patients and enhances their likelihood of success on important medications."

Dr. Sharifah Sarhan, MB BAO BCh, Medical Science Liaison at HealthBeacon, added: "This latest published research by the International Journal of Clinical Pharmacy adds to the growing portfolio of evidence demonstrating HealthBeacon's ability to have a tangible benefit on patient medication compliance. HealthBeacon's innovative technology is not only seeking to reduce the burden of care on millions of patients that depend on injectable therapies but is proving its ability to do so through real-world data and peer-reviewed evidence."

HealthBeacon's growing customer base currently includes Amryt, Novartis, NHS, HSE, Sanofi, Accord Healthcare, Clonmel Healthcare, Teva, Viatris, and AbbVie.

The Company remains focused on expanding its client base within pharmaceutical companies, specialty pharmacy, healthcare organisations and governments as it targets the deployment of 100,000 Smart Sharps Bin units by the end of 2023.

Enquiries:
HealthBeacon: Laurence Flavin	Investor.Relations@HealthBeacon.com
Goodbody (Euronext Growth Adviser and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Billy Murphy	+353 (0) 87 231 3085
Cathal Barry	+353 (0) 87 227 9281

Ends

Notes

In this latest research on the benefits of HealthBeacon's technology, published by the International Journal of Clinical Pharmacy, real world adherence data was collected from almost 10,000 HealthBeacon patients and compared to existing adherence data in literature.

The research results found that HealthBeacon's adherence was higher overall for patients on therapy for a range of medical conditions. For HealthBeacon patients on dermatological and gastroenterological treatments specifically, adherence was 24% and 26% higher respectively than those without access to the system. Furthermore, the proportion of those with 'optimal' adherence of 80% or greater, was also higher amongst HealthBeacon groups. The study also reported nearly identical adherence rates for males and females when using the ICMS, helping to close a gender gap in previously reported adherence rates.

The International Journal of Clinical Pharmacy is a bimonthly peer-reviewed medical journal covering all aspects of clinical pharmacy and related practice-oriented subjects. The journal was established in 1965 and is published by Springer Science+Business Media, a German multinational publishing company of books, e-books and peer-reviewed journals in science, humanities, technical and medical publishing.

The research on HealthBeacon's innovative technology was also presented at the most recent ESPACOMP conference, the annual flagship symposium held by the International Society for Medication Adherence.

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The Company operates in 17 countries primarily across Europe, North America and the United Kingdom employs more than 50 people and has obtained more than 30 design and utility patents. HealthBeacon's mission is to become the world's leading digital therapeutics platform for injectable medications.

Ends

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISELBLLLLLLLBBD